Microfluidic solutions for PLGA encapsulation of APIs

PLGA microencapsulation of drugs is a popular choice for drug formulation teams due to the biodegradability of PLGA particles and their ability to control drug release over time. Coatings can extend the circulation lifetime, while ligands and antibodies can target specific sites for drug release.

Our Drug (API) Microencapsulation System can efficiently generate micrometre size particles, offering precise control over size and physical characteristics to optimize drug delivery with biodegradable polymers.


Get a quote

Microfluidic technology & benefits


Microfluidics, or “lab-on-a-chip” technology, provides precise control and manipulation of fluids in the micro to picolitre range and can be used to manipulate living matter.

Dolomite is pioneering the use of microfluidic devices for small-scale fluid control and analysis, enabling engineers and scientists to take full advantage of the following :

Traditional methods (batch) Microfluidic methods
API Encapsulation efficiency up to 30% up to 99 %
Coefficient of variation (CV) up to 20% up to 1%
Particle size distribution Broad Narrow
Particle monodispersity Poor Narrow
Waste ~50% Near 0%
Reproducibility Low High
Particle size control Poor Precise
Microfluidic Drug (API) Encapsulation

API encapsulation in PLGA particles

PLGA particles produced using microfluidic systems offer numerous benefits for drug delivery applications such as:

  • enhanced control over each stage of particle fabrication process
  • greater particle yields
  • ease of scale-up

In drug delivery, precise particle production is essential for controlled and sustained release of drugs using biodegradable polymers such as PLGA particles. Drug (API) Microencapsulation Systems offer advantages like enhanced control over particle fabrication, greater yields, and ease of scale-up. Targeted drug delivery is also possible by functionalizing particle surfaces or using the EPR effect. The release profiles of the polymer-drug matrix can be adjusted by varying factors like polymer molecular weight, lactide to glycolide ratio, drug concentration, and particle size.

Get your 30-min free consultation

Speak to our expert

What’s in the Drugs (APIs) Encapsulation system box?

System specifications

Droplet size

Particle size from 50 nm to 50 µm in diameter (depending on system version)

Droplet monodispersity

Extremely monodisperse, CV < up to 1%.

Droplet generation frequency Up to 10 kHz for a standard system and up to a MHz for a Telos® production system (depending on reagents and droplet sizes).
Flow rate range

From 70 nL/min to 5 mL/min, depending on pressure, viscosity and channel geometry (flow resistance).

Flow pressure

Flexible with vacuum and pressure capability in the same pump (pump pressure range: 0-10 bar). Pumps contain integrated reservoir to eliminate the risk of vial fracture in operation.

Chemical resistance

Very high (wetted materials: glass, PEEK, ETFE, FEP, PTFE).



Further reading

Drug delivery studies

Drug delivery studies

A Dolomite microfluidic system is helping Dr Samar Damiati, Assistant Professor in the Biochemistry Department at King Abdulaziz University in Saudi Arabia, perform drug encapsulation studies.

Core shell microparticle production

Core shell microparticle production

In this webinar, we discuss our expertise in hydrophilic drug (API) encapsulation in PLGA microparticles.

Continuous Microfluidic Synthesis of PLGA Microparticles by Droplet Method
Application Notes

Continuous Microfluidic Synthesis of PLGA Microparticles by Droplet Method

Methodology for fabrication of highly monodisperse PLGA beads with sizes ranging from 10 to 45μm using the Droplet Method on Dolomite’s API Encapsulation System and a 3D Flow Focusing Chip.

Don’t know where to start?

Get a quick quote!

Leave your contact information and we will be in touch within 24h!